Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out - Reuters
Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"the trial miss was a significant setback that could curb demand for CagriSema, temper long-term sales hopes and leave Novo struggling to win back share in the fast-growing obesity treatment market."
— J.P. Morgan analysts , Executive
"Sigo siendo muy optimista con respecto a CagriSema."
— Mike Doustdar , Executive
Key People
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPaTdmamc4QU9IekYyT2hOdlVOdlowVjFnZE84b29mN3RuNXFUMURRaUEwTUkzMEwxVllJT3NzdHo3ZjNoYmJmZk41QUpkSTRacmdCd2ZpSVkxdE1icFVXUVVOVUExblRobUpuT2FUSV8td3dCUS00dm5NYU5LYmFTTEdLT0lhQm9naEczT2lySU9GSS1ZUFpEZnNCemFVUk9lejMxR2RBVFNScFBRamlpbEpjQU1iX0RmVjlJVXZJR0k2T2dGZkJWVWItaDY4czE3YkdTT1Fab05tUQ?oc=5" target="_blank">Novo Nordisk's $475-billion rise and fall as Wegovy-era gains wiped out</a> <font color="#6f6f6f">Reuters</font>
Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
Novo Nordisk shares fell more than 15% on Monday, wiping away the last gains Wegovy’s launch had brought, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly’s tirzepatide in a trial.
Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining gains brought by its blockbuster weight-loss drug Wegovy, after the drugmaker said its next-generation obesity drug CagriSema underperformed Eli Lilly's rival.
Novo Nordisk ha sufrido una nueva caída en Bolsa tras anunciar que los ensayos clínicos de su nuevo medicamento contra la obesidad, CagriSema, no alcanzaron el criterio principal de efectividad frente a su competidor Tirzepatida, comercializado por Eli Lilly.
Similar Stories
Related coverage based on topic and tags
Boots has a new owner: Three ways it could affect you
The stalwart of Britain's High Street has been sold to a Canadian billionaire family. What will that mean for you?
October 9, 2026 at 11:01 PMDental firm vVardis reveals revenue surge in US IPO filing - Reuters
Dental firm vVardis reveals revenue surge in US IPO filing Reuters
October 9, 2026 at 07:31 PM'People don't think recycling at work is part of their job description'
Unclear labelling as well as a lack of recycling facilities at work or in public-facing businesses is an issue.
October 9, 2026 at 07:11 PMFour signs it is about to get uglier in the bond market as yields rise - Reuters
Four signs it is about to get uglier in the bond market as yields rise Reuters
October 9, 2026 at 04:18 PMBASF considers raising offer for Evonik, sources say - Reuters
BASF considers raising offer for Evonik, sources say Reuters
October 9, 2026 at 02:02 PMReport highlights flaws in ADHD and autism care
There is a risk of people being over-diagnosed with ADHD and autism, an official review in England has found.
October 9, 2026 at 01:52 PM